TRIPLE-NEGATIVE BREAST CARCINOMA
Clinical trials for TRIPLE-NEGATIVE BREAST CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new TRIPLE-NEGATIVE BREAST CARCINOMA trials appear
Sign up with your email to follow new studies for TRIPLE-NEGATIVE BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise in shrinking aggressive breast tumors before surgery
Disease control CompletedThis study tested a combination of chemotherapy (nab-paclitaxel) and immunotherapy (atezolizumab) given before surgery to women with triple-negative breast cancer. The goal was to shrink tumors and reduce the amount of breast tissue that needs to be removed. 37 participants were …
Matched conditions: TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 02:07 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-stage trial tested a new drug (AZD8186) combined with chemotherapy (docetaxel) in 23 people with advanced solid tumors that have certain gene mutations (PTEN or PIK3CB). The main goals were to find the best dose and check for side effects. The study was completed, but …
Matched conditions: TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:00 UTC
-
New hope for tough breast cancer: drug cocktail shrinks tumors before surgery
Disease control CompletedThis study tested a combination of three drugs (panitumumab, carboplatin, and paclitaxel) given before surgery to women with triple-negative breast cancer whose tumors did not respond to standard chemotherapy. The goal was to shrink the tumor enough to remove less breast tissue. …
Matched conditions: TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 02:00 UTC
-
New combo shrinks aggressive breast tumors before surgery
Disease control CompletedThis study tested whether adding two drugs (carboplatin and bevacizumab) to standard chemotherapy before surgery could improve outcomes for people with a fast-growing type of breast cancer called triple-negative. About 450 participants received weekly paclitaxel with or without t…
Matched conditions: TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:00 UTC
-
New combo shrinks hard-to-treat breast tumors before surgery
Disease control CompletedThis study tested a combination of enzalutamide (a hormone blocker) and paclitaxel (chemotherapy) given before surgery to people with a specific type of triple-negative breast cancer that has androgen receptors. The goal was to see if this treatment could shrink tumors and reduce…
Matched conditions: TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 13, 2026 16:02 UTC